Literature DB >> 19749457

Chemotherapy in adult soft tissue sarcoma.

A Jain1, K V Sajeevan, K G Babu, K C Lakshmaiah.   

Abstract

Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms. Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma. This review gives an outline of chemotherapy and the newer targeted therapies for the same. We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma. The available data from the literature is mainly composed of the most recent reviews, meta-analyses, phase II, and randomized phase III trials published in various peer reviewed journals and various international conferences. The role of neoadjuvant and adjuvant chemotherapy has been found to be controversial. The recent meta-analysis for adjuvant therapy in STSs has shown an increase in the overall survival with combination of ifosfamide and adriamycin. In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication. The combination of ifosfamide and adriamycin may also be used for rapid symptom relief and in patients planned for curative resection for metastases. Newer combinations of docetaxel and gemcitabine appear promising in selected subgroups, especially in leiomyosarcoma and malignant fibrous histiocytoma. Some recent developments include the European Union's approval of trabectedin for advanced STSs patients who had progressed on adriamycin and ifosfamide therapy. The future of mTOR inhibitors, insulin like growth factor receptor inhibitors and anti-angiogenic drugs appear quite promising. Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials. At the end of each section we have also presented recommendations from FNx01European Society of Medical Oncology and FNx08National Comprehensive Cancer Network guidelines v.1.2009 for better correlation with the present literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19749457     DOI: 10.4103/0019-509X.55547

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  13 in total

1.  Surgery for liver metastases originating from sarcoma-case series.

Authors:  Maximilian Zacherl; Gerwin A Bernhardt; Johannes Zacherl; Gerald Gruber; Peter Kornprat; Heinz Bacher; Hans-Jörg Mischinger; Reinhard Windhager; Raimund Jakesz; Thomas Grünberger
Journal:  Langenbecks Arch Surg       Date:  2011-07-08       Impact factor: 3.445

2.  The surprising outcome of a giant primary mediastinal synovial sarcoma treated with neoadjuvant chemotherapy.

Authors:  Marcos Alexandre Balieiro; Agnaldo José Lopes; Bruno Pinheiro Costa; Gustavo Perissé Moreira Veras; Paulo Sergio Perelson; Rodolfo Acatauassú Nunes; Eduardo Haruo Saito
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

Review 3.  Resectable pancreatic metastasis of left thighbone leiomyosarcoma: case report and literature review.

Authors:  Pierre-Emmanuel Robert; David Orry; Caroline Mor; Philippe Rosset; Serge Guyetant; Ephrem Salame; Loïk de Calan
Journal:  J Gastrointest Cancer       Date:  2012-03

4.  Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases.

Authors:  Ali Murat Sedef; Fatih Köse; Özlem Doğan; Tarkan Ergün; Ahmet Sezer; Hüseyin Mertsoylu; Sadik Muallaoğlu; Ayberk Beşen; Özgur Özyilkan
Journal:  Mol Clin Oncol       Date:  2014-11-13

5.  Primary intracranial leiomyosarcoma in an immunocompetent patient: case report.

Authors:  Yasunori Fujimoto; Junko Hirato; Akatsuki Wakayama; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2010-11-10       Impact factor: 4.130

6.  Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.

Authors:  E J O Soini; B García San Andrés; T Joensuu
Journal:  Ann Oncol       Date:  2010-07-13       Impact factor: 32.976

7.  The importance of reference gene analysis of formalin-fixed, paraffin-embedded samples from sarcoma patients - an often underestimated problem.

Authors:  Ninna Aggerholm-Pedersen; Akmal Safwat; Steen Bærentzen; Marianne Nordsmark; Ole Steen Nielsen; Jan Alsner; Brita S Sørensen
Journal:  Transl Oncol       Date:  2014-12       Impact factor: 4.243

Review 8.  Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.

Authors:  Sheetal Sharma; Shweta Takyar; Stephanie C Manson; Sarah Powell; Nicolas Penel
Journal:  BMC Cancer       Date:  2013-08-13       Impact factor: 4.430

9.  'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells.

Authors:  Mitsunori Toda; Teruya Kawamoto; Takeshi Ueha; Kenta Kishimoto; Hitomi Hara; Naomasa Fukase; Yasuo Onishi; Risa Harada; Masaya Minoda; Masahiro Kurosaka; Toshihiro Akisue
Journal:  Int J Oncol       Date:  2013-06-28       Impact factor: 5.650

10.  Cardiac dysfunction among soft tissue sarcoma patients in Denmark.

Authors:  Sumitra Shantakumar; Morten Olsen; Thao T Vo; Mette Nørgaard; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2016-04-15       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.